Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Metastatic Renal Cell Carcinoma (mRCC) Clinical Trial

Official title:
Clinical Effectiveness of Second-Line Sunitinib Following Immune-oncologic (IO) Therapy in Patients With Metastatic Renal Cell Carcinoma in the International Metastatic Renal Cell Carcinoma Database (IMDC)

Status Completed

Clinical Trial Summary

The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Renal Cell
Metastatic Renal Cell Carcinoma (mRCC)

Clinical Trial Details

NCT number	NCT04175262
Study type	Observational
Source	Pfizer
Contact
Status	Completed
Phase
Start date	October 31, 2019
Completion date	March 9, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02184416` - Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
Completed	`NCT01514448` - Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib	Phase 4
Recruiting	`NCT05287464` - International Multicentric Study ARON-1
Completed	`NCT01390519` - A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor	N/A